Zavegepant

扎维吉泮

Report date: 2025/12/05 14:35:57
NME

Base Information

Drug NameZavegepant
Drug Alias NameVazegepantZavegepant hydrochlorideZAVZPRETBHV-3500BMS-742413 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcitonin gene-related peptide receptor antagonists
TargetsCalcitonin gene-related peptide receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Migraine without AuraMigraine with Aura +[5] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/03/09
Country/TerritoryCanadaUnited StatesTaiwan +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Investment Co Ltd
Inactive CompaniesBiohaven Pharmaceutical Holding Co Ltd
Active IndicationsMigraine without AuraMigraine with AuraMigraine Disorders
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Asthma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG